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T cells play a pathogenic role in many autoimmune diseases, including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis (MS). MS and the mouse model, experimental autoimmune encephalomyelitis (EAE), are chronic inflammatory diseases of the central nervous system ([@bib1]), which until recently were assumed to be mediated by Th1 cells ([@bib2]). However, IFN-γ KO mice have an increased susceptibility to EAE ([@bib3]), and disease is exacerbated in mice deficient in the Th1-polarizing cytokine IL-12 ([@bib4]). In contrast, induction of disease is blocked in mice deficient in the novel IL-12 family member, IL-23 ([@bib4]), which promotes the differentiation of IL-17--producing (ThIL-17) cells ([@bib5], [@bib6]). The demonstration that adoptive transfer of autoantigen-specific ThIL-17 cells, but not Th1 cells, induced EAE ([@bib6]), as well as studies in collagen-induced arthritis ([@bib7]), has established a definitive pathogenic role for these cells in T cell--mediated autoimmune diseases.

Recent reports have demonstrated that ThIL-17 cells are a distinct subtype from Th1 and Th2 cells and do not share a precursor intermediate ([@bib8], [@bib9]). Indeed, their differentiation process is inhibited by the signature Th1 and Th2 cytokines, IFN-γ and IL-4 ([@bib8]). IL-23 can act on effector and memory CD4^+^ T cells to induce T cell proliferation and IL-17 secretion ([@bib5]), but it can also promote the differentiation of naive T cells into ThIL-17 cells ([@bib8], [@bib9]). ThIL-17 cells may function in autoimmunity by promoting the induction of IL-1β and TNF-α. It has been shown that IL-1β and TNF-α can mediate inflammatory pathology in many autoimmune diseases, and antibodies or receptor antagonists of these inflammatory cytokines are effective therapeutics. In rheumatoid arthritis, IL-17 is thought to play a major role upstream of IL-1 ([@bib10], [@bib11]) in promoting autoimmune joint destruction. Furthermore, studies with IL-1RI^−/−^ mice have established a role for IL-1 in the induction of EAE ([@bib12]). In addition, IL-1β is present in MS lesions and families with a high IL-1β to IL-1 receptor antagonist (IL-1Ra) production ratio are at a greater risk of having a relative with relapse-onset MS than those with a low ratio ([@bib13]). However, the precise role of IL-1 in the pathogenesis of EAE is unclear.

We demonstrate that IL-23 alone is a poor stimulus for T cell IL-17 production and that IL-1 is essential for its induction. Immunization with foreign or self-antigens and a Toll-like receptor ligand or CFA demonstrated that IL-1 plays a vital and selective role in promoting antigen-specific ThIL-17 cells in vivo. Furthermore, a failure to induce EAE in IL-1RI^−/−^ mice was associated with a failure to generate ThIL-17 cells. IL-1 acted directly on T cells in synergy with IL-23 to promote IL-17 secretion. TNF-α also synergized with IL-23 to induce IL-17, but this was dependant on IL-1. Our findings demonstrate a central role for IL-1 upstream of IL-17 in promoting autoimmunity in EAE by driving the differentiation of pathogenic ThIL-17 cells.

RESULTS AND DISCUSSION
======================

IL-1RI is required for the induction of ThIL-17 cells
-----------------------------------------------------

In a study on the role of IL-1RI in the adjuvant effect of the Toll-like receptor agonist LPS, we discovered that IL-1 is selectively required for induction of ThIL-17 cells. Parenteral immunization of C57BL/6 mice with KLH in the presence of LPS induced antigen-specific T cells that secreted IFN-γ, IL-10, and IL-17, whereas immunization with KLH in the absence of adjuvant induced little or no antigen-specific cytokine production ([Fig. 1 A](#fig1){ref-type="fig"}). Immunization of IL-1RI^−/−^ mice with KLH and LPS also induced antigen-specific IFN-γ and IL-10 production. However, antigen-specific IL-17 production was significantly lower in IL-1RI^−/−^ than in wild-type C57BL/6 mice. Antigen- specific proliferation was not significantly different between the groups (not depicted). IL-17 concentrations induced by PMA and anti-CD3 were also significantly lower in cells from IL-1RI^−/−^ mice ([Fig. 1 B](#fig1){ref-type="fig"}). Thus, IL-1 is selectively required for antigen or anti-CD3 and PMA-induced IL-17 production.

![**IL-1RI is required for induction or activation of antigen-specific ThIL-17 T cells.** (A) C57BL/6 or IL-1RI^−/−^ mice were immunized s.c. with 10 μg KLH either alone or with 10 μg LPS. Inguinal lymph nodes were harvested after 7 d and cells were restimulated with medium or 2, 10, or 50 μg/ml KLH. (B) Lymph node cells were restimulated with medium or 20 ng/ml PMA and 1 μg/ml anti-CD3. Supernatants were collected after 3 d, and IL-4, IL-10, IL-17, and IFN-γ concentrations were determined by ELISA. C57BL/6 versus IL-1RI^−/−^: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](jem2031685f01){#fig1}

IL-1RI--deficient mice are resistant to EAE, and this correlates with reduced autoantigen-specific IL-17 production
-------------------------------------------------------------------------------------------------------------------

We next examined the possibility that IL-1 may function in the pathology of EAE by promoting pathogenic autoantigen-specific ThIL-17 cells. Wild-type C57BL/6 mice developed severe EAE after immunization with myelin oligodendrocyte glycoprotein (MOG) and CFA. In contrast, the incidence of EAE (2/15 IL-1RI^−/−^ vs. 13/15 in C57BL/6) was considerably lower in IL-1RI^−/−^ mice ([Fig. 2 A](#fig2){ref-type="fig"}). This is consistent with studies indicating an important role for IL-1 in EAE ([@bib12], [@bib14]). However, we demonstrate that the resistance of IL-1RI^−/−^ mice to the development of EAE correlates with a specific defect in activating autoantigen-specific ThIL-17 cells ([Fig. 2 B](#fig2){ref-type="fig"}). MOG-specific IL-17 production was selectively reduced in IL-1RI^−/−^ mice in comparison with wild-type mice ([Fig. 2 B](#fig2){ref-type="fig"}). MOG-specific proliferation and secretion of IL-6, IL-10, and TNF-α were comparable in IL-1RI^−/−^ and wild-type mice. Production of IFN-γ was reduced, but to a modest extent (twofold reduction compared with a 22-fold reduction in IL-17 production).

![**The induction of EAE and autoantigen-specific ThIL-17 cells is dependent on functional IL-1RI.** C57BL/6 or IL-1RI^−/−^ mice were injected with 150 μg MOG in 200 μl CFA and 500 ng PT followed 2 d later with a second dose of PT. Mice were observed for clinical symptoms of EAE daily for 48 d. A separate group of mice were killed on d 21, and spleen cells were restimulated with MOG peptide. After 3 d, supernatants were collected and cytokine concentrations were determined by ELISA. Cell proliferation was determined on day 4 of culture by \[^3^H\]thymidine incorporation. (A) Disease scores (*n* = 15) ± SD. (B) Antigen-specific cytokine production and proliferation. C57BL/6 versus IL-1RI^−/−^: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. (C) IL-1RI^−/−^ mice (*n* = 7) were injected with MOG in CFA followed by PT as described above or with MOG-specific T cells (9 × 10^6^ cells/mouse) generated from the spleens of C57BL/6 mice with EAE. Disease scores (*n* = 5) ± SD.](jem2031685f02){#fig2}

We examined the ability of MOG-specific T cells from wild-type mice to induce EAE in IL-1RI^−/−^ mice and compared this with standard EAE induction. Transfer of a MOG-specific T cell line from C57BL/6 mice with advanced EAE into IL-1RI^−/−^ mice induced EAE in five out of five mice, whereas mice injected directly with MOG and CFA did not develop disease ([Fig. 2 C](#fig2){ref-type="fig"}), demonstrating that IL-1RI is dispensable in the development of EAE after induction of the autoantigen-specific ThIL-17 T cells. Our data support findings that neuroantigen-specific ThIL-17 cells can transfer EAE ([@bib6]) and suggest that the major role of IL-1 in the development of EAE is in promoting pathogenic ThIL-17 cells. The clinical symptoms in EAE are ameliorated by blocking IL-17 ([@bib9], [@bib15]), and injection of anti--IL-17 delays the onset of disease and prevents the characteristic mononuclear cell infiltrate in spinal cord white matter ([@bib9]). Our data place IL-1 upstream of IL-17 and suggest that the efficacy of blocking IL-1 as a therapy for EAE may reflect a failure to activate ThIL-17 cells.

IL-1 synergizes with IL-23 to promote T cell IL-17 production
-------------------------------------------------------------

Because our data pointed to a selective effect of IL-1 in promoting ThIL-17 cells, we determined whether IL-1 directly induced IL-17 secretion by T cells in vitro. Stimulation with rIL-23 induced IL-17 production by spleen cells from C57BL/6 but not from IL-1RI^−/−^mice ([Fig. 3 A](#fig3){ref-type="fig"}). However, production of IL-17 in response to IL-23 alone was relatively low. Furthermore, IL-1 alone did not induce IL-17 secretion by spleen cells but significantly augmented IL-23--induced IL-17 production. Intracellular cytokine staining revealed that IL-17 was produced by CD3^+^ T cells ([Fig. 3 B](#fig3){ref-type="fig"}). Furthermore, the addition of anti--IFN-γ increased the frequency of IL-17--secreting T cells after stimulation with IL-1 and IL-23, consistent with a negative effect of IFN-γ on IL-17 production ([@bib9]).

![**IL-1 synergizes with IL-23 to promote IL-17 production by spleen cells and purified CD4^+^ and CD8^+^ T cells.** (A) Spleen cells (10^6^ cells/ml) from C57BL/6 or IL-1RI^−/−^ mice were cultured with 100 pg/ml IL-23 alone or together with 1 ng/ml IL-1α, and supernatants were collected after 3 d for analysis of IL-17 and IFN-γ by ELISA. C57BL/6 versus IL-1RI^−/−^: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. IL-1α plus IL-23 versus IL-23; \#, P \< 0.001. (B) Spleen cells (2.25 × 10^6^ cells/ml) from C57BL/6 mice were cultured for 48 h with medium or cytokines and for the last 4 h in the presence of 10 μg/ml brefeldin A. Intracellular staining for IL-17 and IFN-γ was performed. Percentages refer to IL-17 production by gated CD3^+^ T cells. Splenic CD4^+^ (C) and CD8^+^ (D) T cells (5 × 10^5^cells/ml) from C57BL/6 mice were incubated with 10 U/ml IL-2 and 1 μg/ml anti-CD3 antibody alone or together with 0.1--1 ng/ml IL-23 and/or 1 ng/ml IL-1α or IL-1β. IL-17 concentrations were measured by ELISA in supernatants collected after 3 d. IL-23 plus IL-1 versus IL-23 only: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](jem2031685f03){#fig3}

To determine whether the synergistic effect of IL-1 on IL-23--induced IL-17 production was mediated directly on T cells or required accessory cells, we assessed the effects of IL-1 and IL-23 on purified T cells. CD4^+^ and CD8^+^ T cells from C57BL/6 mice were stimulated with IL-23 in the presence or absence of IL-1. IL-23 at concentrations of up to 1 ng/ml did not induce significant IL-17 production ([Fig. 3 C](#fig3){ref-type="fig"}). However, the addition of IL-1α or IL-1β resulted in a dramatic synergistic effect with IL-23 in promoting IL-17 secretion. Both CD4^+^ and CD8^+^ T cells have been implicated in the pathology of MS ([@bib16]) and EAE, and ThIL-17 T cells have been shown to induce EAE ([@bib6]). Collectively with our data, these findings suggest that the requirement for IL-1RI to promote ThIL-17 cells and EAE reflects the need for synergy between IL-1 and IL-23 to induce IL-17 production.

To address whether the effects of IL-23 and IL-1 involved amplification of a TCR-activated pathway, we examined the effects of IL-1 and IL-23 in the presence or absence of anti-CD3. IL-1-- and IL-23--induced IL-17 production was retained in the absence of anti-CD3 ([Fig. 4 A](#fig4){ref-type="fig"}). Recent studies have indicated that IL-23 acts by promoting the survival and expansion of ThIL-17 T cells ([@bib17]). Analysis of IL-17 mRNA by real-time PCR revealed that IL-23 or IL-1 and IL-23, but not IL-1 alone, induced potent IL-17 gene transcription ([Fig. 4 B](#fig4){ref-type="fig"}). Therefore, our data suggest that IL-23 is vital for induction of IL-17 mRNA expression. The recently documented ability of IL-6 and TGF-β to promote the differentiation of ThIL-17 cells ([@bib17]--[@bib19]) may be dependant on IL-1. We have found that IL-6 can synergize with IL-23 to promote IL-17 production, but this effect was abrogated in cells from IL-1RI^−/−^ mice (not depicted). Alternatively, IL-1 and IL-23 may act independently of IL-6 and TGF-β to promote IL-17 production from T cells. However, the relative roles of IL-23, IL-6, TGF-β, and IL-1 in the differentiation and survival of ThIL-17 cells require further investigation.

![**IL-1 and IL-23 promote IL-17 production in the absence of TCR stimulation via stimulation of PI3K, NF-κB, and PKCθ.** (A) Splenic CD3^+^ cells (5 × 10^5^ cells/ml) from C57BL/6 mice were incubated with 10 ng/ml IL-1β, 10 ng/ml IL-23, IL-1 and IL-23, or medium only in the presence or absence of anti-CD3, and supernatants were collected at 12, 24, 48, or 72 h for analysis by ELISA. (B) Splenic CD3^+^ cells from C57BL/6 mice were incubated with 1 μg/ml anti-CD3 for 2 h before stimulation with IL-1, IL-23, IL-1 and IL-23, or medium. IL-17 mRNA expression was evaluated by real-time PCR 48 h after stimulation, and the data represent the fold change for IL-17 mRNA in relation to 18S rRNA. IL-23 plus IL-1 versus IL-23 only: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. (C) CD3^+^ cells (5 × 10^5^ cells/ml) were stimulated with medium (control) or with IL-23, IL-1, or IL-23 and IL-1 with or without anti-CD3 in the presence or absence of (30-min pretreatment) LY294002 (PI3K inhibitor at 20 and 40 μM), BAY 11-7082 (NF-κB inhibitor at 4 and 8 μM), rottlerin (novel PKC inhibitor at 10 and 100 μM), UO126 (ERK inhibitor at 5 μM), or SB203580 (p38 inhibitor at 5 μM). Supernatants were collected 3 d later for analysis of IL-17 production by ELISA. IL-23 plus IL-1 versus IL-23 plus IL-1 plus inhibitor: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. (D) CD3^+^ cells were incubated with medium only or with IL-1, IL-23, or IL-1 and IL-23. Cell lysates were analyzed by Western blotting with antibodies specific for phosphorylated Akt and IκB-α or β-actin as a loading control.](jem2031685f04){#fig4}

Our data suggest that in addition to roles for IL-23, as well as CD28 and ICOS costimulation ([@bib9]), in promoting the differentiation of naive T cells into ThIL-17 cells, there is an additional and central requirement for IL-1.

Signaling pathways involved in IL-1-- and IL-23--induced IL-17 production
-------------------------------------------------------------------------

Using specific inhibitors of intracellular signaling pathways, we found that novel isoforms of protein kinase C (PKC), NF-κB, and PI3K are essential for IL-1 and IL-23 to promote IL-17 production by T cells ([Fig. 4 C](#fig4){ref-type="fig"}). These inhibitors completely blocked IL-1-- and IL-23--induced IL-17 production, which was observed in the presence or absence of TCR stimulation, indicating that the cytokines can activate signaling pathways that directly promote IL-17 production.

PKCθ-deficient mice are resistant to EAE and this correlates with reduced IL-17 in the central nervous systems of these mice ([@bib20]). Our data support an important role for PKCθ ([@bib21]) in IL-1-- and IL-23--mediated induction of T cell IL-17 production. We also demonstrate that PI3K and NF-κB are important in the induction of IL-17 ([@bib22]) and that phosphorylation of Akt (a readout for PI3K activation) and IκB-α were induced independently by IL-1 and IL-23 ([Fig. 4 D](#fig4){ref-type="fig"}). It was reported that MAP kinase pathways are involved in IL-17 transcriptional regulation in human T cells ([@bib23]). We demonstrate that in murine cells, inhibitors of ERK (UO126) and p38 (SB203580) did not inhibit IL-17 and, notably, ERK inhibition enhanced IL-17 production ([Fig. 4 C](#fig4){ref-type="fig"}). However, in the absence of TCR stimulation, inhibition of p38 reduced IL-17 production in response to IL-1 and IL-23.

TNF-α enhances IL-23--induced IL-17 by an IL-1--dependent mechanism
-------------------------------------------------------------------

In addition to IL-1, TNF-α has been shown to play a major role in the inflammatory pathology in T cell--mediated autoimmune diseases and other chronic inflammatory conditions. Drugs targeting either IL-1 or TNF-α are effective therapeutics for these diseases. It has been assumed that TNF-α and IL-1 mediate inflammatory reactions downstream of the effects of T cells. However, the spontaneous arthritis that develops in IL-1Ra^−/−^ mice does not occur in T cell--deficient mice ([@bib24]) or mice deficient in IL-17 ([@bib25]), whereas IL-17 is enhanced in IL-1Ra^−/−^ mice ([@bib25]). We found that TNF-α alone did not induce IL-17 production by spleen cells but did synergize with IL-23 to promote IL-17 production ([Fig. 5](#fig5){ref-type="fig"}). This effect was dependent on IL-1, which is consistent with reports that TNF-α can promote IL-1 production and stromal cell IL-1RI expression ([@bib26]) and that IL-1 was inhibited by treatment of psoriasis patients with a soluble TNF receptor ([@bib27]). We found that TNF-α, but not IL-1 or IL-23, increased expression of IL-1RI on both CD4^+^ and CD8^+^ T cells (not depicted), which may enhance their responsiveness to IL-1.

![**TNF-α promotes IL-23--induced IL-17 production in an IL-1--dependent manner.** Spleen cells (10^6^ cells/ml) from C57BL/6 or IL-1RI^−/−^ were cultured with 1 ng/ml IL-23, 0.01--1 ng/ml TNF-α, 0.01--1 ng/ml IL-23 and TNF-α, medium, or PMA and anti-CD3. Supernatants were collected after 3 d for analysis of IL-17 and IFN-γ production by ELISA. C57BL/6 versus IL-1RI^−/−^: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. TNF-α plus IL-23 versus IL-23: \#, P \< 0.05; \#\#, P \< 0.01; \#\#\#, P \< 0.001.](jem2031685f05){#fig5}

Because there are complex cytokine networks operating at sites of inflammation, several cytokines, including IL-23, IL-1, and TNF-α, may contribute to amplify IL-17 production. For example, IL-17 can synergize with TNF-α and IL-1 to promote inflammatory gene expression ([@bib28]). Our demonstration that IL-1 acts upstream of IL-17 in EAE, combined with findings that IL-17 can promote IL-1, indicates that there may be a "vicious circle" with IL-1 and IL-17 promoting each other and amplifying the autoimmune response.

Our findings provide further evidence for a role of innate immune responses in directing adaptive immunity. Specifically, in addition to the established proinflammatory role of IL-1, our findings reveal a hitherto unrecognized regulatory role for IL-1α and IL-1β in selectively promoting pathogenic ThIL-17 cells that mediate autoimmunity.

MATERIALS AND METHODS
=====================

Mice.
-----

C57BL/6 and IL-1RI^−/−^ mice were obtained from Harlan Ltd. and bred at Trinity College Dublin under specific pathogen-free conditions. Mice were maintained according to the regulations of the European Union and the Irish Department of Health.

Immunization experiments.
-------------------------

Mice were immunized s.c. in the flank with KLH (10 μg per mouse; endotoxin-free; Calbiochem) alone or together with LPS (10 μg per mouse; *Escherichia coli*, serotype R515; Qbiogene), or with PBS. Mice were killed after 7 d and inguinal lymph nodes were removed.

Induction and assessment of EAE.
--------------------------------

C57BL/6 and IL-1RI^−/−^ mice were immunized s.c. with 150 μg MOG peptide 35-55 (Cambridge BioSciences) emulsified in CFA supplemented with 5 mg/ml killed *Mycobacterium tuberculosis* (Chondrex). For the adoptive transfer studies, EAE was induced in C57BL/6 mice and when mice reached an average disease score of 4, spleens were harvested and cultured with 16 μg/ml MOG, 10 ng/ml IL-1, and 10 ng/ml IL-23 for 3 d. Cells were washed and injected i.v. (9 × 10^6^ per mouse) into IL-1RI^−/−^ mice. Mice were injected i.p. with 500 ng pertussis toxin (PT; Sigma-Aldrich) on days 0 and 2. From day 2, mice were observed daily for signs of clinical disease. Disease severity was recorded as follows: grade 0, normal; grade 1, limp tail; grade 2, wobbly gait; grade 3, hind limb weakness; grade 4, hind limb paralysis; and grade 5, tetraparalysis/death.

Antigen-specific proliferation and cytokine production.
-------------------------------------------------------

Lymph node cells (10^6^ cells/ml) were stimulated with 2--50 μg/ml KLH, 20 ng/ml PMA (Sigma-Genosys), and 1 μg/ml anti--mouse CD3 (BD Biosciences), or medium only. Alternatively, spleen cells (2 × 10^6^ cells/ml) from mice with EAE were cultured with MOG (4 or 20 μg/ml), or medium only. Supernatants were collected after 72 h and cytokine concentrations were determined by ELISA using antibody pairs specific for IL-4, IFN-γ, IL-6 (BD Biosciences), IL-17, TNF-α, or IL-10 (Duo-Set; R&D Systems.). On day 4, 1 μCi/well \[^3^H\]thymidine (GE Healthcare) was added and the cells were cultured for an additional 6 h, after which cells were harvested and proliferation was assessed by \[^3^H\]thymidine incorporation (1450 Microbeta; PerkinElmer).

T cell purification.
--------------------

Mouse T cell CD4 and CD8 subset column kits (R&D Systems) were used to purify CD4^+^ and CD8^+^ cells from the spleens of C57BL/6 mice. T cell purity was routinely \>95%. T cells and spleen cells were incubated with IL-1α, IL-1β, TNF-α, and IL-23 (endotoxin content was \<1 EU/μg protein in all cases; R&D Systems) alone or in combination. In the studies on intracellular signaling pathways, all inhibitors were obtained from Calbiochem. For experiments on purified T cells, IL-2 (Hoffman-La Roche Inc.) and anti-CD3 were also included except where stated.

Intracellular cytokine staining.
--------------------------------

Spleen cells from C57BL/6 mice were incubated for 72 h with medium or cytokines in the presence of 10 μg/ml brefeldin A (for the last 4 h) before extracellular staining with anti-CD3. Cells were washed, blocked with 1 μg/ml of Fcγ blocker (BD Biosciences), fixed, permeabilized (Fix and Perm cell permeabilization kit; Caltag), and stained with anti--IL-17, anti--IFN-γ antibody, or the appropriate isotype control. Flow cytometric analysis was performed using a FACSCalibur flow cytometer (Becton Dickinson).

Western blotting.
-----------------

CD3^+^ cells (10^6^ cells/ml) were purified from the spleens of C57BL/6 mice and incubated with 10 ng/ml IL-1, 10 ng/ml IL-23, or IL-1 and IL-23 in the presence or absence of 1 μg/ml anti-CD3. Cell lysates were prepared and resolved on 12% SDS-PAGE gels, transferred onto nitrocellulose membranes, and blocked. Membranes were incubated with antibodies specific for phospho-Akt and phospho-IκBα (Cell Signaling Technology) and β-actin (Sigma-Aldrich). After washing, the membranes were incubated with horseradish peroxidase--labeled secondary antibodies for 1 h at room temperature and developed by chemiluminescence (LiteAblot; Euroclone).

Real-time PCR.
--------------

CD3^+^ T cells (3.5 × 10^6^ cells/ml) were stimulated with 1 μg/ml anti-CD3 and 10 ng/ml IL-1, 10 ng/ml IL-23, or IL-1 and IL-23. RNA was harvested from the cells 48 h later using an RNEasy isolation kit (QIAGEN) followed by reverse transcription using a QuantiTect Reverse transcription kit (QIAGEN). Real-time PCR for the detection of IL-17 mRNA was performed using sense and antisense primers for IL-17A (Mm00439619_m1; Applied Biosystems) and a FAM-labeled MGB Taqman probe. 18S ribosomal RNA was used as an endogenous control. Samples were assayed on an Applied Biosystems 7300 PCR machine.

Statistical analysis.
---------------------

Cytokine levels were compared by one-way ANOVA. Where significant differences were found, the Tukey-Kramer multiple comparisons test was used to identify differences between individual groups. Significance of the results from real-time PCR was determined using Newman-Keul\'s test.
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